XTMAB-16 is an anti-TNFa monoclonal antibody currently under investigation. Based on its ability to block TNFa, XTMAB-16 may disrupt an inflammatory pathway and help slow granuloma formation. XTMAB16 Study is a randomized, double-blind, placebo-controlled, Phase 1a/ 2b trial that enrolled 39 patients in dose-ranging study.
Enrollment advances Xentria's partnership with Meitheal Pharmaceuticals, Inc., triggering a milestone payment and supporting ongoing development. Over the course of the partnership, Xentria has secured an upfront payment and remains eligible for additional milestones and potential royalties under the commercialization deal exceeding $600 million .
CHICAGO , March 18, 2025 /PRNewswire/ -- Xentria, a clinical-stage biopharmaceutical company advancing therapies for rare and serious diseases, today announced the successful completion of enrollment in the therapeutic dose-ranging phase of its global XTMAB16 Study in pulmonary sarcoidosis, an immune-mediated inflammatory disorder with few available treatment options. The dose-ranging study successfully enrolled 39 patients across 17 centers in 4 countries, surpassing initial enrollment targets—a testament to both the strong interest in advancing pulmonary sarcoidosis research and the momentum behind XTMAB16's clinical development. The Data Safety Monitoring Committee (DSMC) will carefully evaluate dose-response relationships between the active dose and placebo groups to determine the optimal dose for further in.
